Psychedelics have been shown to have several potential benefits for mental health, including reducing anxiety, depression, and post-traumatic stress disorder (PTSD). However, for these benefits to be realized, it is important to integrate the psychedelic experience into one’s life after the session has ended. This is known as “integration” or “aftercare.”   Psychedelic integration can take many forms, but it typically involves talking to a therapist or counselor about the experience, journaling about it, and making lifestyle changes to support the new insights and perspectives gained dur ..read more

MindBio Therapeutics has announced groundbreaking results from a Phase 2a clinical trial involving the take-home microdosing of MB22001 for treating depression. This world-first trial showcased a significant decrease in depression symptoms over 8 weeks, with a 60% reduction in depressive symptoms and 53% of patients achieving complete remission. The trial achieved its primary efficacy endpoint with an average 14.1 point drop in the Montgomery-Asberg Depression Rating Scale (MADRS), demonstrating the safe and effective use of MB22001 in a take-home setting without any serious treatment-related ..read more

  Palliative care is a crucial aspect of healthcare, aiming to enhance the quality of life for patients facing incurable illnesses. Within this context, the use of medicinal cannabis (MC) has emerged as a potential avenue for addressing various symptoms and improving overall well-being. This article delves into a systematic review conducted by Marjan Doppen and colleagues, which examines the current evidence surrounding MC’s effects and potential harms in palliative care settings. Background: With the growing interest in alternative therapies, medicinal cannabis has garnered attention fo ..read more

As we close out the year, let’s take a look back at some of the more important milestones in the psychedelic medicine space. From legalization to clinical trials, the psychedelic sector continued to make steady progress on all fronts. Here are some of the top psychedelic stories of 2023.     Australia Legalization Early in 2023, we received big breaking news on the legalization front as Australia rescheduled certain psychedelics for therapeutic use. Australia became the first nation to specifically legalize psychedelics, as the nation’s Therapeutic Goods Administration (TGA) will pe ..read more

  Terran Biosciences Receives FDA Clearance for NM-101, the industry’s first software for the analysis of neuromelanin-sensitive MRI   MIAMI–(BUSINESS WIRE)–Terran Biosciences, Inc. (“Terran”), a biotech platform company developing therapeutics and technologies for patients with neuropsychiatric illnesses, has received FDA clearance to market NM-101, a cloud-based software platform to analyze neuromelanin-sensitive MRI scans. Currently, there is no other FDA-cleared software indicated for the analysis of neuromelanin MRI on the market, making Terran’s technology the world’s first. N ..read more

Welcome to the News You Might Have Missed, a weekly roundup of psychedelic medicine news to help you catch up and stay informed   MindMed Announces Positive Results from Phase 2b Anxiety Trial Big news for LSD fans and MindMed investors as the Phase 2b trial met its primary endpoint, with 50% clinical remission rate in the 100 µg dose group at Week 4 MM-120 (MindMed’s form of LSD) at 100 µg demonstrated a clinically and statistically significant HAM-A reduction of 21.3 points, representing a 7.6-point improvement over placebo The company plans to hold an End-of-Phase 2 meeting with the F ..read more

I recently had the pleasure of talking with and meeting Stephanie Wang, the founder and CEO of Ka, who has dedicated her life to helping people achieve full-spectrum wellness and aliveness. Through her journey from finance to plant medicine and psychedelics, she discovered the power of Kana, a natural serotonin reuptake inhibitor and serotonin-releasing agent, which can calm and uplift individuals simultaneously. In a recent interview with the Mindfulness Experience podcast, Wang shared her expertise on the power of plants for conscious evolution and her session at the Wonderland Miami 2023 C ..read more

MindMed Announces Positive Topline Results from Phase 2b Trial of MM-120 in Generalized Anxiety Disorder   – Trial met its primary endpoint with MM-120 demonstrating a statistically significant dose-dependent improvement in HAM-A scores four weeks after a single-dose  – MM-120 100 µg demonstrated a clinically and statistically significant HAM-A reduction of 21.3 points, representing a 7.6-point improvement over placebo at Week 4 (p=0.0004, Cohen’s d effect size = 0.88)  – Clinical response rate of 78% in 100 µg and 200 µg dose groups and 50% clinical remission rate in the 100 ..read more

MAPS PBC Announces Submission of New Drug Application to the FDA for MDMA-Assisted Therapy for PTSD   Filing marks first NDA submission for any psychedelic-assisted therapy  Submission represents 30 plus years of clinical research into potential use of MDMA-assisted therapy for PTSD NDA includes two Phase 3 trials (MAPP1 and MAPP2) that both met primary and secondary endpoints SAN JOSE, Calif., Dec. 12, 2023 /PRNewswire/ — MAPS Public Benefit Corporation (“MAPS PBC”), a clinical-stage company dedicated to changing the way mental health conditions are treated, announ ..read more

Tryp Therapeutics Inc. Announces Signing of Definitive Agreement with Exopharm Limited   ELOWNA, BC / ACCESSWIRE / December 11, 2023 / Tryp Therapeutics Inc. (“Tryp” or the “Company“) (CSE:TRYP), a clinical-stage biotechnology company focused on developing intravenous-infused psilocin (the active metabolite of psilocybin) for diseases with high unmet medical needs, is pleased to announce that the Company has entered into an arrangement agreement (the “Arrangement Agreement“) with Exopharm Limited ACN 163 765 991 (“Exopharm” or the “Purchaser“) dated as of December 8, 2023, purs ..read more